Sphera Funds Management LTD Lowered Its Sarepta Therapeutics INC (Call) (SRPT) Stake by $10.49 Million; Stock Value Rose

January 17, 2018 - By Maria Brooks

Investors sentiment increased to 2.88 in Q3 2017. Its up 1.36, from 1.52 in 2017Q2. It improved, as 24 investors sold SRPT shares while 27 reduced holdings. 63 funds opened positions while 84 raised stakes. 51.70 million shares or 25.22% more from 41.29 million shares in 2017Q2 were reported. Trexquant Investment Ltd Partnership has invested 0.1% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Fmr Ltd holds 2.02 million shares or 0.01% of its portfolio. Sectoral Asset Mgmt has invested 0.4% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Nationwide Fund Advsr holds 32,906 shares. Parkside Natl Bank And Trust reported 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Eam Ltd Liability Com reported 0.37% stake. Tekla Capital Management Lc holds 0.87% or 536,600 shares. Price T Rowe Assoc Md holds 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 782,781 shares. Jennison Associate Lc holds 0.05% or 1.14 million shares in its portfolio. Schwab Charles Inv Management holds 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 268,553 shares. Hanson Mcclain reported 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Granite Point Cap Management L P, a Massachusetts-based fund reported 46,520 shares. Jpmorgan Chase And reported 317,800 shares. Morgan Stanley holds 0% or 261,122 shares in its portfolio. Teacher Retirement Sys Of Texas invested in 0% or 4,897 shares.

Since October 3, 2017, it had 0 insider purchases, and 1 sale for $575,000 activity.

Sphera Funds Management Ltd decreased its stake in Sarepta Therapeutics Inc (Call) (SRPT) by 60.84% based on its latest 2017Q3 regulatory filing with the SEC. Sphera Funds Management Ltd sold 233,047 shares as the company’s stock rose 22.49% with the market. The institutional investor held 150,000 shares of the health care company at the end of 2017Q3, valued at $6.80M, down from 383,047 at the end of the previous reported quarter. Sphera Funds Management Ltd who had been investing in Sarepta Therapeutics Inc (Call) for a number of months, seems to be less bullish one the $3.89 billion market cap company. The stock decreased 2.23% or $1.37 during the last trading session, reaching $60.15. About 2.04M shares traded or 13.40% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since January 17, 2017 and is uptrending. It has outperformed by 80.12% the S&P500.

Sphera Funds Management Ltd, which manages about $700.90 million US Long portfolio, upped its stake in Celgene Corp (NASDAQ:CELG) by 25,000 shares to 275,000 shares, valued at $40.10M in 2017Q3, according to the filing. It also increased its holding in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 105,000 shares in the quarter, for a total of 145,000 shares, and has risen its stake in Cellectis S A.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on February, 27. They expect $-0.35 EPS, up 77.85 % or $1.23 from last year’s $-1.58 per share. After $-0.78 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -55.13 % EPS growth.

More important recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Seekingalpha.com which released: “Sarepta Therapeutics: A Top 2018 Pick” on January 03, 2018, also Seekingalpha.com published article titled: “Sarepta Therapeutics: Continued Upside In 2018”, Seekingalpha.com published: “Sarepta: Rosy Prospects Continue, Buying On Dips” on January 15, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was released by: Globenewswire.com and their article: “Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule …” with publication date: December 29, 2017.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Sarepta Therapeutics had 95 analyst reports since August 5, 2015 according to SRatingsIntel. Janney Capital initiated the stock with “Buy” rating in Wednesday, January 3 report. The rating was initiated by Goldman Sachs on Tuesday, December 20 with “Neutral”. The firm has “Equal-Weight” rating given on Wednesday, January 4 by Morgan Stanley. The rating was upgraded by RBC Capital Markets to “Outperform” on Wednesday, August 26. The firm earned “Buy” rating on Wednesday, June 28 by Credit Suisse. RBC Capital Markets maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Wednesday, March 1. RBC Capital Markets has “Outperform” rating and $91 target. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Tuesday, September 12 by Cowen & Co. The firm has “Buy” rating given on Tuesday, August 25 by Vetr. The rating was upgraded by Leerink Swann to “Outperform” on Thursday, March 2. The stock has “Buy” rating by Roth Capital on Wednesday, August 5.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.